6610.TWO TWi Biotechnology, Inc.

Healthcare Biotechnology Taiwan OTC Exchange
18.10 TWD
Close of Nov 6, 2026
14.35 57.20
Market cap
TWD 4.05B
P/E
-
P/B
8.48x
ROE
-56.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 6610.TWO undervalued?

Graham number

The Graham number of TWi Biotechnology, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

TWi Biotechnology, Inc. fundamental analysis

No fundamental analysis for TWi Biotechnology, Inc. yet.

TWi Biotechnology, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About TWi Biotechnology, Inc.

TWi Biotechnology, Inc., a clinical-stage biopharmaceutical company, develops and sells drugs for innate immunity-related diseases in Taiwan. The company development pipeline comprises AC-203, which is in Phase 2 clinical trial for various indications, including epidermolysis bullosa simplex, epidermolysis bullosa, arthritis, gout, and diabetes mellitus; AC- 1101, which is in Phase Ib trial for the treatment of vitiligo and preclinical stage for the treatment of atopic derma…

Full company profile